Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.06.22	Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis (EQS Group)
24.04.17	Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing... (PR Newswire)
21.04.17	New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year (PR Newswire)
12.12.16	Astellas Announces Transfer of Qutenza™ to Grünenthal (PR Newswire)
14.01.16	Astellas Pharma Europe: Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer (Businesswire)
01.03.10	OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma (Businesswire)
13.07.09	New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (Businesswire)
16.12.08	OSI Pharmaceuticals Announces the Appointment of Mr. Pierre Legault as Executive Vice President and Chief Financial Officer (Businesswire)
03.09.08	OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821 (Businesswire)
21.02.08	OSI Pharmaceuticals Announces Year End 2007 Financial Results (Businesswire)
13.06.07	OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board (Businesswire)
05.01.07	OSI Pharmaceuticals Licenses Its Glucokinase Activator Program for the Treatment of Type 2 Diabetes to Eli Lilly and Company (Businesswire)
07.08.06	OSI Pharmaceuticals Announces Second Quarter 2006 Financial Results (Businesswire)
04.05.06	OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting (Businesswire)
21.04.06	OSI Pharmaceuticals Announces Three Additions to Its 2006 Board of Director Slate; David Niemiec, Skip Klein, Santo Costa are Nominated as New Directors (Businesswire)
07.03.06	OSI Pharmaceuticals Announces Year End 2005 Financial Results (Businesswire)
24.02.06	Systemic Safety Profile of Macugen(R) (pegaptanib sodium injection) Maintained Throughout Two Years with No Increased Risk of Cardiovascular Events (Businesswire)
16.12.05	OSI Pharmaceuticals, Inc. Prices $100 Million 2.00% Convertible Senior Subordinated Note Offering (Businesswire)
14.12.05	OSI Announces Proposal to Offer $100 Million of Convertible Senior Subordinated Notes (Businesswire)
10.11.05	OSI Pharmaceuticals Updates Status of Pending Acquisition of Eyetech Pharmaceuticals (Businesswire)
14.09.05	FDA Advisory Panel Recommends Tarceva(R) Approval for Pancreatic Cancer; Committee Supports New Indication for EGFR Inhibitor Tarceva (Businesswire)
21.08.05	OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Accretive and Generate Combined 2006 Revenues of Over $600 Million (Businesswire)
16.05.05	Data from Tarceva-TM- Clinical Trial Program Presented at American Soc (Businesswire)
07.02.05	OSI Pharmaceuticals Announces Transition Quarter Financial Results; Co (Businesswire)
19.01.05	OSI Pharmaceuticals's Diabetes and Obesity Subsidiary, Prosidion, Ini (Businesswire)
04.01.05	OSI Pharmaceuticals to Present at the JP Morgan Annual Healthcare Conf (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Astellas Pharma Inc.

Aktien Top/Flop

Astellas Pharma Peer Group Nachrichten

Meistgelesene Nachrichten